GGT1 and neoplasm: Single agent of GGT1 inhibitor has the ability to inhibit the RASmut tumor cells [128], and inhibition of both FT and GGT1 markedly reduced RAS‐driven tumor growth and completely inhibit the prenylation in the preclinical setting [125, 129, 130].